biological origin

The world's largest producer of generic drugs - an Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd. announced its withdrawal from the Association of the U.S. generics (GPhA) at the end of June this year

In a letter to the Association, sponsored by the president and CEO of Teva North America, William March, said that Teva will be on their own behalf, because GPhA doing this is not enough.

"Unfortunately, in its current state GPhA unable to properly reflect the policy priorities and market realities of the company" - he writes.

Representatives of the association, which was headed by William March to February of this year, a request to comment on the situation did not respond.

Teva Decision to withdraw from the Association made after the recent enactment of health reform in the U.S., which makes a difference in the generic pharmaceutical industry sector, because expanding access to generic drugs and, at the same time, be possible to resolve patent disputes in court.

Buy Cialis Tadalafil Order Cialis Online Cheap Cialis Generic Cialis 20mg NO Prescription
Viagra Online Sildenafil 100mg Buy Viagra Discount Canadian Pharmacy Generic Viagra Brand Name
Order Viagra Online Generic Levitra Cheap Cialis Drug Without Prescription

However, the law provides a 12-year patent protection for drugs of biological origin before the market can appear bioshozhie funds. For traditional chemical drugs patent term is 5 years.
Bioshozhie drugs may be one of the most important aspects of the development of generic sector. Projected to Teva, the 2015 market size of generic medicines analogues of biological origin may reach $ 200 billion. Teva already sells a number of such drugs in Europe.

The letter also stated that Teva will continue to cooperate with PGhA on many issues of mutual interest.

Although the core business of the Israeli company is the production of generics, it sells a number of well-established brands, including drug for multiple sclerosis treatment Copaxone. It is not clear whether Teva intends to join any other association, in particular the Association of pharmaceutical researchers and manufacturers of the U.S. (PhRMA) and the American Association for the biotechnology industry.